Clinical Trial: Prognostic Study on Discontinuation After Combined PEG-IFNα-2b Therapy in Chronic Phase CML Patients Who Met TKI Discontinuation Criteria Following TKI Treatment (China)

Posted On: 2026-08-21

China, Aug. 21 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Prognostic Study on Discontinuation After Combined PEG-IFNα-2b Therapy in Chronic Phase CML Patients Who Met TKI Discontinuation Criteria Following TKI Treatment'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130452

Registration Time: 2026/08/20

Type: Interventional study

Primary Sponsor: The 2nd Affiliated Hospital of Chongqing Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339192

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Prognostic Study on Discontinuation After Combined PEG-IFNα-2b Therapy in Chronic Phase CML Patients Who Met TKI Discontinuation Criteria Following TKI Treatment (China)